Physicians, scientists, and allied health staff from Mayo Clinic and Mayo Medical Laboratories are currently attending Digestive Disease Week (DDW) in Washington. In addition to being represented by numerous presentations and abstracts (search "Mayo Clinic"), Mayo Medical Laboratories representatives will be available at booth #3425 in the exhibit hall to discuss:
- INFLIXIMAB: Reflexive testing method benefits patients and reduces cost
- LYNCH SYNDROME: Targeted tests and NGS panel provide cost-effective and flexible approach to testing
- GI INFECTIONS: Testing to yield rapid identification of the causative agents
- AUTOIMMUNE GI DYSMOTILITY: Successful identification can result in early diagnosis of an associated cancer and reversibility of symptoms with immunotherapy
- CELIAC DISEASE: Comprehensive cascade requires only 2 tests in 87% of cases
The new Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered to assess a trough level quantitation for evaluation of patients with loss of response to infliximab.
- Maria Willrich, Ph.D. gives a video overview of the Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum [A Test in Focus]
- Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum [Test Catalog]
The American Cancer Society estimates that there will be 93,090 new cases of colon cancer diagnosed in 2015, with hereditary colon cancer syndromes accounting for approximately 10% of those cases. It’s important to identify the hereditary colon cancer cases because of the important ramifications for the affected individual and their family members. Once hereditary colon cancer mutations have been identified within the family, genetic testing can facilitate the identification of other at-risk family members. This allows clinicians to utilize early screening and monitoring options that optimize potential for early detection of colon cancer.
- Hereditary Colon Cancer Multi-Gene Panel [A Test in Focus]
- Single Gene vs. Multiple Gene Testing [A Test in Focus]
- Hereditary Colon Cancer: Comprehensive Testing Options [Informational PDF]
Mayo Clinic's microbiology laboratories span all areas of conventional and molecular microbiology. Our laboratories perform over 2.8 million tests annually and have developed and implemented culture techniques, immunoassays, and molecular methods for rapid detection and identification of microbial pathogens.
AUTOIMMUNE GI DYSMOTILITY
Identification of autoimmune gastrointestinal dysmotility (AGID) can result in early diagnosis of an associated cancer and reversibility of symptoms with immunotherapy.
- Autoimmune Gastrointestinal Dysmotility (AGID) Evaluation: An Update [Hot Topic]
- Autoimmune Gastrointestinal Dysmotility Evaluation, Serum [Test Catalog]
- Autoimmune Gastrointestinal Dysmotility Evaluation [Algorithm]
The National Institute of Health (NIH) has reported that as many as 1% (3,000,000) of all Americans have celiac disease and hundreds of thousands of these patients are undiagnosed. In fact, the time to diagnosis currently averages 10 years from the onset of symptoms.
Laboratory algorithms using a reflex approach provide an alternative to ordering individual tests when evaluating a patient with suspected celiac disease. The goal of algorithms is to provide the most appropriate selection of tests for each patient, while maintaining the highest possible sensitivity and specificity. And, in fact, analysis of Mayo Clinic practice data found that the cascade approach required only 2 tests in 87% of cases.
- New Test Algorithms for Celiac Disease: An Efficient and Cost-Effective Diagnostic Approach [Featured Topic]